The Johnson & Johnson (J&J) adenovirus-based COVID-19 vaccine is 74% reliable in staying clear of SARS-CoV-2 infection also amid phases of high Alpha (B117) and Delta (B1617.2) different circulation, follow to the preliminary findings of a real-world US study yesterday in JAMA Network Open.

You are watching: How good is the johnson and johnson vaccine

The comparative-effectiveness study, led by researchers from nference, a Massachusetts software company affiliated with Janssen, maker of the J&J vaccine, involved mining the mei Clinic digital health records (EHRs) that 8,889 vaccinated and 88,898 suitable unvaccinated adult living in 1 the 15 says from Feb 27 come Jul 22, 2021.

The EHRs to be from the multistate mayo Clinic health System. Men consisted of roughly half of both teams of patients, v a mean period of 52.4 years in the vaccinated group and 51.7 in the unvaccinated group.

Participants had one or more COVID-19 exam at mei Clinic during the study period and stayed in an area in which at least 10 patients had received the J&J vaccine. Average follow-up was 111 days.

Almost 4-fold palliation in infections

Sixty that 8,889 vaccinated patients (0.7%) and 2,236 the 88,898 unvaccinated patient (2.5%) tested positive for COVID-19. The incidence rate ratio in the group vaccinated with the single-dose J&J COVID-19 vaccine matches the unvaccinated group was 0.26 (95% to trust interval , 0.20 come 0.34), for a vaccine efficiency of 73.6% (95% CI, 65.9% come 79.9%) and a 3.73-fold reduction in infections.

When the researcher analyzed the number of hospitalizations, intensive care unit (ICU) admissions, and deaths amongst the 60 vaccinated and 2,236 unvaccinated patients who tested positive for SARS-CoV-2, a composite outcome verified 67% vaccine protection against severe COVID-19 (odds proportion , 0.33 <95% CI, 0.19 come 0.65>).

A subgroup evaluation showed reduced odds that hospital join (OR, 0.32 <95% CI, 0.18 to 0.66>) and ICU join (OR, 0.00 <95% CI, 0.00 come 1.43>), however not death (OR, 0.83 <95% CI, 0.26 to 5.20>) amongst the vaccinated.

One vaccinated patient and 12 in the unvaccinated team died. The researchers stated that, with just 60 patients in the vaccinated group trial and error positive for COVID-19, the study was underpowered to certainly measure protection against death.

Findings align v those the clinical trials

"This study’s findings are continual with the clinical trial-reported efficacy the Ad26.COV2.S and the first retrospective analysis, saying that the vaccine is efficient at reducing SARS-CoV-2 infection, even with the spread out of variants such as Alpha or Delta that were not current in the initial studies, and reaffirm the urgent require to proceed mass vaccination efforts globally," the writer concluded.

The research is the first to use EHR data in a propensity score-matched retrospective analysis of J&J vaccine effectiveness, according to the researchers.

See more: How Do I Make My Router Secure Your Router And Home Network, How Do I Make My Router More Secure

"Implementation that this structure will permit us to track in real time just how the effectiveness of this 1-shot vaccine proceeds to evolve end the comes weeks and also months," lock wrote. "This details is particularly important in the paper definition of the introduction of variants that can potentially to escape vaccine-induced immunity."

The Food and Drug management issued emergency use authorization because that the J&J vaccine ~ above Feb 27, 2021. Since then, more than 21 million doses have actually been administered in the joined States, the researcher noted.